Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer-Reference-Cited by-同舟云学术

Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

Published:2019-09-06 Issue:2 Volume:146 Page:439-448
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Ray‐Coquard Isabelle¹^ORCID,Cibula David²,Mirza Mansoor R.³,Reuss Alexander⁴,Ricci Caterina⁵,Colombo Nicoletta⁶,Koch Horst⁷,Goffin Frédéric⁸,González‐Martin Antonio⁹,Ottevanger Petronella B.¹⁰,Baumann Klaus¹¹,Bjørge Line¹²¹³,Lesoin Anne¹⁴,Burges Alexander¹⁵,Rosenberg Per¹⁶,Gropp‐Meier Martina¹⁷,Harrela Maija¹⁸,Harter Philipp¹⁹,Frenel Jean‐Sébastien²⁰,Minarik Tomas²¹,Pisano Carmela²²,Hasenburg Annette²³,Merger Michael²⁴,Bois Andreas¹⁹,

Affiliation:

1. GINECO and Medical Oncology Department, Centre Léon BérardUniversity Claude Bernard Lyon Lyon France

2. AGO and Oncogynecologic Center, Department of Obstetrics and Gynecology, General Faculty HospitalCharles University of Prague Prague Czech Republic

3. NSGO and Department of OncologyRigshospitalet Copenhagen University Hospital Copenhagen Denmark

4. AGO and Coordinating Center for Clinical TrialsPhilipps‐University of Marburg Marburg Germany

5. MITO and Division of Gynecologic Oncology, Department of Women and Children's Health and Public HealthFondazione Policlinico Gemelli IRCCS Rome Italy

6. MaNGO and European Institute of Oncology and University of Milan Bicocca Milan Italy

7. AGO Austria and Department of Obstetrics and GynecologyParacelsus Medical University Salzburg Austria

8. BGOG and CHU de LiègeUniversity of Liège Liège Belgium

9. GEICO and Medical Oncology DepartmentClínica Universidad de Navarra Madrid Spain

10. DGOG and Department of Medical OncologyRadboud University Medical Centre Nijmegen The Netherlands

11. AGO and Department of GynecologyKlinikum der Stadt Ludwigshafen GmbH Ludwigshafen Germany

12. NSGO and Department of GynecologyHaukeland Universitetssykehus Bergen Norway

13. Center for Cancer Biomarkers CCBIO, Department of Clinical ScienceUniversity of Bergen Bergen Norway

14. GINECO and Department of Gynecologic Cancer and Medical OncologyCentre Oscar Lambret Lille France

15. AGO and Department of Obstetrics and GynecologyUniversity Hospital LMU Munich Germany

16. NSGO and Department of OncologyUniversity Hospital Linköping Linköping Sweden

17. AGO and Department of Gynecology and ObstetricsOberschwabenklinik, Krankenhaus St. Elisabeth Ravensburg Germany

18. NSGO and Department of Gynoncology and Gynecology and ObstetricsKymenlaakso Central Hospital Kotka Finland

19. AGO and Department of Gynecology and Gynecologic OncologyKliniken Essen Mitte Essen Germany

20. GINECO and Centre René GauducheauInstitut de Cancerologie de l'Ouest Saint Herblain France

21. NSGO and National Institute of Oncology Bratislava Slovakia

22. MITO and Department of Uro‐Gynecologic OncologyIstituto Nazionale per Io Studio e la Cura dei Tumori ‘Fondazione G. Pascale’ IRCCS Naples Italy

23. AGO and Department of Obstetrics and GynecologyUniversity Medical Center Mainz Germany

24. Oncology MedicineBoehringer Ingelheim International GmbH Biberach Germany

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32606

Reference23 articles.

1. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

2. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

3. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

4. A Phase 3 Trial of Bevacizumab in Ovarian Cancer

5. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives;Current Opinion in Obstetrics & Gynecology;2023-12-04

2. Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer;Frontiers in Immunology;2023-10-23

3. Adipocyte-derived CCDC3 promotes tumorigenesis in epithelial ovarian cancer through the Wnt/ß-catenin signalling pathway;Biochemistry and Biophysics Reports;2023-09

4. Discovery of a new potent oxindole multi-kinase inhibitor among a series of designed 3-alkenyl-oxindoles with ancillary carbonic anhydrase inhibitory activity as antiproliferative agents;BMC Chemistry;2023-07-18

5. Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors;Current Cancer Drug Targets;2023-07